Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate
Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD
Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year
From Oxford: Carlo Rinaldi's team has received two grants from Oxford-Harrington Rare Disease Centre to develop treatments for Spinal-bulbar muscular atrophy (SBMA) and Friedreich's ataxia
From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases



BiotechTV - News